Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
By Anna Azvolinsky, LiveScience Contributor Published: 12/04/2013 03:25 PM EST on LiveScience A sensitive new DNA test can predict how long ovarian cancer patients will survive, and guide personalized treatment decisions, according to new research. 
No comment yet.
Sign up to comment
|
Scoop.it!
We have developed a novel approach to categorize immunity in patients that uses a combination of whole blood flow cytometry and hierarchical clustering.
Alfredo Corell's insight:
Conclusions
Comprehensive multi-factorial immune analysis resulting in immune profiles were prognostic, uncovered relationships among immune markers and identified a potential biomarker for the prognosis of cancer. Immune profiles may be useful to streamline evaluation of immune modulating therapies and continue to identify immune based biomarkers.
|
The technology, called QuanTILfy, counts the number of cells called tumor-infiltrating lymphocytes (TILs) in a cancer patient's tumor biopsy. Cancer patientswith more of these cells in their tumor tend to have better outcomes, previous studies in ovarian, colorectal and other cancers have shown.
A divulgative new in spanish: http://www.elmundo.es/salud/2013/12/09/52a0d4010ab740f5568b458f.html ;
The original publication
Sci Transl Med 4 December 2013:
Vol. 5, Issue 214, p. 214ra169
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007247
http://stm.sciencemag.org/content/5/214/214ra169.short ;